Urgent.News

What's breaking now, across hundreds of outlets.

AI

Designing Healthcare AI to Identify Medication Affordability Barriers

Medication-related AI commonly focuses on drug interactions, prescription optimisation, adverse event prediction and medication adherence. However, an important factor is often overlooked: can the patient afford the medication? A patient may understand the prescription and be willing to follow treatment but still be unable to purchase the medicine. This presents an opportunity for healthcare data…

When designing artificial intelligence for healthcare, it is crucial not to overlook the issue of medication affordability. Many AI systems concentrate on drug interactions, prescription optimization, adverse event prediction, and medication adherence. However, one key aspect is often neglected: can patients afford the prescribed medication?

Even if a patient understands their treatment plan and is willing to follow it, financial constraints may prevent them from obtaining the necessary medicine. This presents an opportunity for healthcare data science to address this challenge.

To tackle medication affordability, several factors must be considered. Medicine prices, insurance coverage, household income, geographical availability, and recurring treatment expenses can all impact a patient's ability to access the medication they need. A missed refill might not always indicate intentional non-adherence; sometimes, it simply reflects an inability to purchase the medication.

Therefore, a healthcare AI system should distinguish between observed medication access patterns and the underlying reasons for them.

To develop an affordability intelligence system, relevant data sources must be utilized responsibly. These sources could include verified medicine pricing, insurance coverage details, dispensing and refill records, patient-reported financial barriers, and information on medicine availability. Linking these data sources should be done with proper consent, privacy controls, and data governance measures in place.

A potential workflow for such a system could involve identifying a patient whose medication refill has been delayed. Instead of automatically flagging the event as non-adherence, the system could examine available information for potential affordability barriers. If necessary, it should seek clarification or recommend a conversation with a healthcare professional.

Once relevant data is obtained, the system could generate a report showcasing verified cost information and potential assistance pathways to help the patient obtain the medication they require.

However, it is essential to recognize that cost optimization cannot exist independently of clinical suitability. A cheaper medication might have different contraindications, interactions, formulations, or dosing requirements. Any proposed alternative must undergo proper professional review before implementation. In the case of agentic AI systems, comparing prices and preparing recommendations may be acceptable, but changing a prescription requires appropriate clinical authority and governance.

When evaluating the effectiveness of an affordability intelligence system, several measures should be considered. Affordability barrier identification accuracy, reliability of price information, referral appropriateness, patient access outcomes, and changes in avoidable treatment interruptions can all be useful evaluation metrics. Researchers should also assess the system's performance across different income groups and healthcare settings to ensure equitable impact.

In conclusion, medication affordability goes beyond mere economic considerations. It directly influences whether treatment is accessible and sustainable for patients. Healthcare AI should not merely identify the necessary medication for a patient but also assess whether they can realistically obtain it. By incorporating affordability intelligence into patient-centered care, healthcare systems can better support patients in managing their treatment plans and improving overall health outcomes.

Rewritten by urgent.news; may contain errors — check the original.

Read the original at dev.to →

Report a problem with this story

More in AI

Your AI-Designed Antibody Binds EGFR. Does It Bind at the Wrong pH?

Imagine your model gives you two antibodies. Both bind the human epidermal growth factor receptor (EGFR) about equally well at pH 6.5. You repeat the experiment at pH 7.4. One still binds strongly. The other gives you a curve you can barely distinguish from background.

  • G532 antibody shows weaker binding at neutral pH of 7.4.
  • Control antibody exhibits stronger binding at the same pH level.
  • Researchers suggest investigating weaker-binding antibodies for tumor tissue targeting.

More from Saturday 21 November →